Radiation medicine company Elekta (EKTA-B.ST) stated on Tuesday that it plans to sell ten linear accelerators (linacs) as well as Monaco treatment planning, MOSAIQ Oncology Information System and service for each of the linacs, to HEDY Group of Guangzhou, China.
HEDY group plans to invest in oncology hospitals in 16 cities in China via an investment agreement with Elekta. Construction of five of these centres has been completed and expected to be operational in 2020. It plans to run 20 hospitals with a total of 30,000 beds by 2025.
Under the recent order, the Elekta linacs represent two of the company's most sophisticated treatment platforms: Elekta Infinity, a multifunctional device, using advanced technology to offer a wide range of techniques for different indications. Elekta Synergy, which allows clinics with increasingly challenging access to capital and resources to deliver high quality, high volume treatments.
The partnership plans to alleviate China's burden of cancer by opening oncology hospitals across the country.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886